AlphAIAlphAI — Financial news for AI agents
investing.com$CBIO

Stifel reiterates Buy on Crescent Biopharma stock, $28 target

Stifel maintained a Buy rating and $28 target on Crescent Biopharma (NASDAQ:CBIO) after FDA clearance of its CR-002 drug. The stock trades at $13.94, down 28% in six months. Stifel expects trial data in 2027. Crescent raised $143.7M in a public offering. H.C. Wainwright upgraded CBIO to Buy with a $36 target.

Original reporting
investing.com
Published Oct 6, 2026, 12:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$CBIO
Bullish
high confidence
Mentioned
$CBIO
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CBIOBullishMed
01

Why it matters

The FDA IND clearance for CR-002 is a catalyst that could lift CBIO ahead of Phase 1/2 data expected in H2 2027, supporting Stifel's higher price target.

02

Market read

Regulatory approval for a small‑cap biotech often triggers short‑term price appreciation and increased analyst coverage.

03

What to watch

Potential competition from Henlius and Pfizer ADCs and the need for substantial data to justify the valuation.

Relevance 8/10Novelty 8/10Timing: today

Background

Crescent Biopharma recently completed a $143.7 million public offering, strengthening its balance sheet for upcoming trials.

Company-level read

Ticker impact

$CBIOBullishHigh confidence
Context

Stifel reiterated a Buy rating and raised the price target to $28 after the FDA cleared Crescent Biopharma's IND for CR-002, a new clinical asset.

Expected impact

upward pressure as investors price in the upcoming Phase 1/2 data and the higher target

Evidence & confidence

Regulatory approval is a material event for a biotech; the new $28 target implies ~50% upside from current levels.

Market effects

Sector

Positive for the broader oncology ADC sector as FDA clearance may boost confidence in similar pipelines.

Regional

U.S. biotech market may see modest gains from the news.

Global

Limited to investors focused on U.S. biotech and specialty pharma.

Counterpoint

What could challenge this read

If the upcoming trial data disappoint, the stock could face a sharp correction despite the clearance.

Key entities

  • Analyst
    Stifel

    Maintained Buy rating and set $28 target.

  • Regulator
    FDA

    Cleared IND for CR-002.

Read at source← All news

Related articles

$CBIOMed

H.C. Wainwright reiterates Crescent Biopharma stock rating at buy

H.C. Wainwright reiterated a Buy rating and $36.00 price target on Crescent Biopharma (CBIO), citing progress in mid-stage clinical trials for its CR-001 drug. The stock trades at $11.84, with potential upside of over 200%. Crescent announced completion of dose escalation in its ASCEND trial and enrollment of over 125 patients. The company aims to dose over 2,000 patients by mid-2027 and start Phase 3 trials in early 2028.

investing.com
$CBIOHighAI 8/10

Stifel reiterates Crescent Biopharma stock rating on pipeline progress

Stifel maintained a Buy rating and $28.00 price target for Crescent Biopharma (CBIO) after its pipeline update, noting progress in trials and patient dosing. The stock, trading at $12.48, has dropped 16% in a week. Crescent recently raised $143.7M via a public offering, with H.C. Wainwright upgrading its rating to Buy with a $36.00 target. The company's enterprise value is below $500M, and it expects to dose over 2,000 patients by mid-2027.

investing.com
$CBIOMed

Crescent Biopharma advances CR-001 combos, clears IND for CR-002 and sets mid‑2027 data timelines

Crescent Biopharma (CBIO) announced enrollment in CR-001 chemo combination cohorts and IND allowance for CR-002, with initial data expected in 2027. The company completed CR-001 monotherapy dose escalation and expects initial monotherapy data from over 125 patients and ORR in up to 12 1L NSCLC patients by Q1 2027. The FDA allowed IND for CR-002, with a global Phase 1/2 APOLLO trial to start Q4 2026 and initial data anticipated in H2 2027.

tradingview.com
$CBIOMed

Crescent Biopharma, Inc. issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x…

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 15, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care

SEC EDGAR 8-K
$CBIOHigh

Crescent Biopharma stock rating upgraded to buy at H.C. Wainwright

H.C. Wainwright upgraded Crescent Biopharma (CBIO) to Buy with a $36.00 price target, citing potential catalysts in 2027. The stock is currently trading at $13.94. The firm highlighted the company's antibody-drug conjugate pipeline and recent public offering raising $143.7 million. CBIO's balance sheet shows more cash than debt, a strength for a clinical-stage biotech.

investing.com